Drugs / AutoSynVax™ vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02992977 | Jan 2017 → Dec 2018 | — | Agenus Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AutoSynVax vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02992977 ↗ |
| Modality | Vaccine | “AutoSynVax™ vaccine” NCT02992977 ↗ |
| Route | Subcutaneous | “every other week subcutaneous injection of 240 μg AutoSynVax™ vaccine” NCT02992977 ↗ |